A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 70
Healthy Volunteers: t
View:

• Adults, adolescents, and children in good general health as assessed by medical history and physical examination (group-specific criteria apply).

• At least 18 months old on the day of screening and not more than 70 years old on the day of vaccination (group-specific criteria apply).

• Participant or parent/guardian willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.

• In the opinion of the Principal Investigator (PI) or designee and based on Assessment of Informed Consent Understanding (AOU), participant or parent/guardian has understood the information provided and potential impact and/or risks linked to administration and participation in the trial; written informed consent will be obtained before any study-related procedures are performed. Children old enough to understand the procedures will be asked to assent, in addition to parent/guardian consent, in accordance with local requirements.

• Willing to undergo HIV testing, risk reduction counselling, and receive HIV test results (group-specific timepoints apply).

• All participants of child-bearing potential engaging in sexual activity that could lead to pregnancy must commit to use an effective hormonal contraception or intrauterine device beginning 2 weeks prior and extending for 4 months following receipt of vaccine/placebo. Study sites will choose which methods are most appropriate for their population and this will be specified in the Informed Consent Document (ICD).

• All sexually active participants must consistently use male or female condoms with all sexual partners for 4 months following IP administration.

• All participants who are not engaging in sexual activity that could lead to pregnancy at screening must agree to utilize an effective method of contraception if they begin engaging in sexual activity that could lead to pregnancy, as outlined above.

• All participants of childbearing potential must be willing to undergo a pregnancy test at time points indicated in the SOA.

• Willing to forgo donation of blood or any other tissues for transfusion or transplantation, from screening onward throughout the course of the study.

⁃ Additional Inclusion Criteria For HIV-Infected Participants

• Adults who are HIV-infected must meet the following additional inclusion criteria:

• Participant must be aged at least 18 years old on the day of screening and not more than 50 years old on the day of vaccination.

• Participant must have documented HIV-1 or HIV-2 infection for at least 6 months prior to screening.

• Participant must be on a stable (at least 6 months) regimen of Highly Active Antiretroviral Therapy (HAART), as defined as potent anti-HIV treatment including a combination of antiretroviral agents (pre- or post-exposure prophylaxis does not count as HAART).

• Participant entering the study should have a screening viral load \<50 copies/ml.

• Participant must be willing to continue their HAART and HIV care follow up throughout the study as directed by their regular caregiver and be willing to give access to records of their ongoing care.

• Participant must be in an otherwise reasonably good medical condition (absence of acquired immunodeficiency syndrome \[AIDS\]-defining illnesses or clinically significant disease), diagnosed based on physical examination, medical history, and the investigator's clinical judgment.

⁃ Additional Inclusion Criteria for Pediatric Participants

• Each potential pediatric study participant must meet all of the following additional criteria to be enrolled in the study:

• Parent(s)/legal guardian must have signed an ICD indicating that they understand the purpose and procedures required for the study, are willing/able to adhere to the study requirements and are willing for their child to participate in the study. Assent must be obtained from adolescents and children in accordance with local regulations and practice. Parent(s)/legal guardian must pass the AOU.

• Participant's age on the day of vaccination is within one of the 3 age strata in the study: 12-17 years, 6-11 years, or 18 months -5 years.

• Participant must be healthy in the investigator's clinical judgment (and the parent(s)/legal guardian's judgment) based on medical history, physical examination and vital signs performed at screening.

• A female adolescent who is of childbearing potential must comply with requirements for contraception.

• Adolescents who are sexually active must comply with requirement for use of condoms for 4 months after vaccination.

• Participant has received all routine immunizations appropriate for their age as reported by the parent(s)/legal guardian, according to local routine vaccination schedules. Participants are allowed to catch up on routine immunizations if needed or as part of national immunization campaigns. However, Exclusion Criteria #9 will apply.

Locations
Other Locations
Ghana
Noguchi Memorial Institute for Medical Research (NMIMR)
RECRUITING
Accra
Liberia
PREVAIL_ John F. Kennedy Medical Center (JFK)
RECRUITING
Monrovia
Nigeria
Walter Reed Program - Nigeria
RECRUITING
Wuse
Contact Information
Primary
Gaudensia Mutua
gmutua@iavi.org
+254-719-043-000
Backup
Babalwa Jongihlati
BJongihlati@iavi.org
NAP
Time Frame
Start Date: 2024-03-06
Estimated Completion Date: 2027-04
Participants
Target number of participants: 612
Treatments
Experimental: Cohort 1A
Healthy Adults, 18-70yrs
Experimental: Cohort 2A
HIV-infected Adults, 18-50yrs
Experimental: Cohort 3A
Adolescents, 12 17yrs
Experimental: Cohort 4A
Children, 6-11yrs
Experimental: Cohort 5A
Children, 18mos-5yrs
Experimental: Cohort 1B
Healthy Adults, 18-70yrs
Experimental: Cohort 2B
HIV-infected Adults,18-50yrs
Experimental: Cohort 3B
Adolescents, 12 17yrs
Experimental: Cohort 4B
Children, 6-11yrs
Experimental: Cohort 5B
Children, 18mos-5yrs
Related Therapeutic Areas
Sponsors
Leads: International AIDS Vaccine Initiative
Collaborators: Coalition for Epidemic Preparedness Innovations

This content was sourced from clinicaltrials.gov